ANALGESIC AND MUSCLE RELAXANT CAPLETS TABLET
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
09-01-2013
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
IBUPROFEN; METHOCARBAMOL
Tillgänglig från:
TEVA CANADA LIMITED
ATC-kod:
M03BA53
INN (International namn):
METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS
Dos:
200MG; 500MG
Läkemedelsform:
TABLET
Sammansättning:
IBUPROFEN 200MG; METHOCARBAMOL 500MG
Administreringssätt:
ORAL
Enheter i paketet:
18/40
Receptbelagda typ:
OTC
Terapiområde:
CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0248961001; AHFS:
Bemyndigande status:
CANCELLED POST MARKET
Tillstånd datum:
2021-08-12
Produktens egenskaper
1 | P a g e
PRODUCT MONOGRAPH
ANALGESIC & MUSCLE RELAXANT CAPLETS
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
TEVA CANADA LIMITED
Date of Preparation:
30 Novopharm Court
January 8, 2013
Toronto, Canada
M1B 2K9
Control# 161025
2 | P a g e
TABLE OF CONTENTS
Clinical Pharmacology
..............................................................................................................................
3
Indications:
................................................................................................................................................
7
Contraindications
......................................................................................................................................
8
Warnings:
..................................................................................................................................................
8
Precautions
..............................................................................................................................................
12
Drug Interactions
....................................................................................................................................
13
Adverse Reactions
..................................................................................................................................
15
Symptoms and Treatment of Overdose
...................................................................................................
17
Dosage and
Administration.....................................................................................................................
18
Pharmaceutical Information
....................................................................................................................
19
Composition:
...........................................................................................................................................
21
Availability of Dosage Forms
..........................
Läs hela dokumentet
